The Ashwell–Morell Receptor (ASGPR): Molecular Mechanisms, Ligand Interactions, and ANT BIO PTE. LTD.’s Research Tools

1. Concept

The asialoglycoprotein receptor (ASGPR), also widely recognized as the "Ashwell–Morell receptor," is a founding member of the mammalian lectin family and a key mediator of glycoprotein metabolism and cellular uptake. Characterized by its high specificity for molecules bearing terminal non-reducing galactose (Gal) or N-acetylgalactosamine (GalNAc) residues, ASGPR plays a multifaceted role in physiological and pathological processes. Beyond its canonical function in clearing circulating asialoglycoproteins, it mediates the uptake of diverse biological substrates, including cellular fibronectin, prothrombotic factors, hepatic lipoproteins, and serum immunoglobulin A (IgA). Additionally, ASGPR’s interaction with pathogen-derived components is implicated in the pathogenesis of infectious liver diseases, highlighting its dual role in homeostasis and host defense. Predominantly expressed on hepatocytes—with substantially lower levels in other cell types—ASGPR’s unique ligand-binding properties and endocytic capacity make it a critical target for basic research and translational applications in hepatology, immunology, and drug development.

2. Research Frontiers

Recent advancements in molecular biology and cell biology have expanded our understanding of ASGPR, with key research frontiers focusing on:

• Structural basis of ligand binding: High-resolution structural studies aim to decipher the molecular interactions between ASGPR’s carbohydrate recognition domain (CRD) and Gal/GalNAc-containing ligands, including the role of calcium ions and specific amino acid residues in mediating binding affinity.
• Regulation of ASGPR expression and function: Investigations into how environmental and pathological factors (e.g., ethanol, lipopolysaccharide, diabetes, partial hepatectomy) modulate ASGPR expression and endocytic activity, shedding light on its dysregulation in liver disease.
• Pathogenic interactions: Research into ASGPR’s role as a host receptor for pathogens, exploring how microbial components bind to ASGPR to mediate liver infection and identifying potential therapeutic targets to block these interactions.
• ASGPR in extra-hepatic tissues: Emerging studies on ASGPR expression in non-hepatic cells (e.g., peritoneal macrophages, sperm, intestinal epithelial cells, and colorectal cancer liver metastases) to uncover previously unrecognized physiological or pathological functions.
• Targeted delivery applications: Leveraging ASGPR’s ligand-binding specificity to develop liver-targeted drug and gene delivery systems, optimizing the efficacy of therapies for liver-associated disorders.

3. Research Significance

ASGPR research holds profound scientific and translational significance across multiple disciplines:

• Molecular physiology: Elucidating ASGPR’s ligand-binding mechanisms and endocytic pathways provides fundamental insights into lectin-mediated cellular uptake, a conserved process critical for nutrient transport, waste clearance, and immune regulation.
• Liver disease pathogenesis: Understanding how ASGPR function is impaired by toxins (e.g., ethanol, carbon tetrachloride) or pathological states (e.g., diabetes) offers new perspectives on the development of chronic liver diseases and potential therapeutic interventions.
• Infectious disease research: Identifying ASGPR as a mediator of pathogen-liver cell interactions opens avenues for developing antiviral/antimicrobial strategies that target this receptor-ligand axis.
• Drug delivery innovation: ASGPR’s hepatocyte tropism and high-affinity ligand binding make it an ideal target for designing liver-specific delivery systems, reducing off-target effects and enhancing the efficacy of drugs for liver cancer, metabolic disorders, and infectious diseases.

4. Relevant Mechanisms, Research Methods, and Product Applications

Core Mechanisms

1. Ligand Recognition: ASGPR is a heterodimeric complex composed of two type II transmembrane subunits (46 kDa and 50 kDa). The CRD of each subunit contains three low-affinity calcium-binding sites, which are essential for ligand binding. Specific amino acid residues in the H1 subunit (e.g., Asp241, Asp265, Asn264, Glu252, Gln239, Trp243) form hydrogen bonds with the 3’ and 4’ hydroxyl groups of Gal/GalNAc, mediating high-affinity interactions. Ligands with multiple sugar moieties (e.g., arabinogalactan, pullulan) form additional hydrogen bonds via a tri-antennary binding mode, enhancing binding stability.
2. Clathrin-Mediated Endocytosis: Ligand binding to ASGPR (optimal at pH 6 and in the presence of calcium ions) triggers the formation of clathrin-coated pits on the hepatocyte plasma membrane. Dynamin-mediated GTP hydrolysis drives the detachment of 100–120 nm clathrin-coated vesicles, which then shed their clathrin coat. The resulting endosomes fuse to form tubular compartments (pH ~6), which are sorted into recycling endosomes or early lysosomes. In lysosomes (pH ~5.4), reduced calcium binding affinity leads to ligand dissociation and degradation, while ASGPR is recycled to the plasma membrane—extending its surface half-life to ~20 hours.
3. Regulation of Expression and Function: ASGPR expression is dynamically regulated by various factors. Toxins (ethanol, carbon tetrachloride, lipopolysaccharide), pro-apoptotic agents (anti-Fas antibodies), metabolic disorders (diabetes), and surgical interventions (partial hepatectomy) can all impair ASGPR expression or endocytic function, contributing to liver dysfunction.

Key Research Methods

• Ligand-Binding Assays: Quantitative binding assays using labeled Gal/GalNAc-containing ligands (e.g., asialoglycoproteins, synthetic glycoconjugates) to measure ASGPR binding affinity and specificity.
• Structural Biology Techniques: X-ray crystallography and cryo-electron microscopy to resolve the 3D structure of ASGPR’s CRD and its interaction with ligands and calcium ions.
• Endocytosis Assays: Fluorescence-based tracking of labeled ligands or receptor-antibody complexes to quantify ASGPR internalization rate, recycling efficiency, and lysosomal targeting.
• Immunodetection and Expression Profiling: Western blotting, immunofluorescence, and flow cytometry to analyze ASGPR expression levels in hepatocytes, extra-hepatic tissues, and diseased samples.
• Functional Inhibition Studies: Use of specific antibodies, siRNAs, or small-molecule inhibitors to block ASGPR function and investigate its role in ligand uptake, pathogen entry, or disease progression.

Product Applications by ANT BIO PTE. LTD.

ANT BIO PTE. LTD.’s specialized product portfolio—STARTER antibodies, UA recombinant proteins, and Absin kits—provides critical tools to advance ASGPR research across molecular mechanisms, functional validation, and translational studies:

• UA Recombinant Proteins: The "Biotinylated ASGR1/ASGPR1 His&Avi Tag Protein, Human (Catalog No.: UA010845)" is expressed in HEK293 cells, ensuring native folding and functional CRD. Key applications include:
• Ligand-binding assays to characterize ASGPR’s interaction with natural or synthetic ligands.
• Structural biology studies to resolve ASGPR-ligand-calcium complexes.
• Validation of ASGPR-targeted drug delivery systems for specificity and binding efficiency.
• STARTER Antibodies: High-specificity antibodies such as "Asialoglycoprotein Receptor 1 Recombinant Rabbit mAb (SDT-292-48) (Catalog No.: S0B0088)" and "ASGR1 Rabbit Polyclonal Antibody (Catalog No.: S0B1374)" enable:
• Specific detection of ASGPR in Western blotting, immunofluorescence, and flow cytometry for expression profiling in normal and diseased tissues.
• Immunoprecipitation of ASGPR to investigate protein-protein interactions or post-translational modifications.
• Tracking of ASGPR internalization and recycling via immunofluorescence microscopy.
• Absin Kits & General Reagents: Specialized kits (e.g., endocytosis assay kits, ligand-binding assay kits) and high-purity reagents (e.g., labeled Gal/GalNAc ligands, calcium chelators, lysosomal markers) support:
• Quantitative measurement of ASGPR-mediated endocytosis and ligand degradation.
• Functional studies on the regulation of ASGPR expression and activity.
• Standardization of assays for validating ASGPR-targeted therapeutics.

5. Brand Mission

At ANT BIO PTE. LTD., our mission is to empower global life science researchers and drug developers with high-quality, innovative, and reliable research tools that accelerate breakthrough discoveries in molecular biology, hepatology, and translational medicine. We are committed to advancing the understanding of key biological receptors like ASGPR by delivering specialized products—including antibodies (STARTER), recombinant proteins (UA), and kits & general reagents (Absin)—that meet the rigorous demands of cutting-edge research. Backed by 15 years of expertise in antibody and protein development, and certifications including EU 98/79/EC, ISO9001, and ISO13485, we strive to bridge the gap between basic research and clinical application. Our dedication to excellence ensures that researchers worldwide have access to the tools they need to unravel complex molecular mechanisms, validate therapeutic targets, and develop life-changing treatments for unmet medical needs.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.